| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| M P Curran, C M Perr. Amisulpride: a review of its use in the management of schizophrenia. Drugs. vol 61. issue 14. 2002-04-02. PMID:11735643. |
in comparative trials, amisulpride administered within this range (400 to 1200 mg/day) was as effective as haloperidol 5 to 40 mg/day, flupenthixol 25 mg/day and risperidone 8 mg/day in patients with acute exacerbations of schizophrenia with predominantly positive symptoms. |
2002-04-02 |
2023-08-12 |
Not clear |
| Uriel Heresco-Levy, Marina Ermilov, Jonathan Shimoni, Baruch Shapira, Gail Silipo, Daniel C Javit. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. The American journal of psychiatry. vol 159. issue 3. 2002-03-14. PMID:11870017. |
placebo-controlled trial of d-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. |
2002-03-14 |
2023-08-12 |
Not clear |
| Uriel Heresco-Levy, Marina Ermilov, Jonathan Shimoni, Baruch Shapira, Gail Silipo, Daniel C Javit. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. The American journal of psychiatry. vol 159. issue 3. 2002-03-14. PMID:11870017. |
the authors investigated the clinical effects of d-cycloserine when added to treatment with conventional neuroleptics, olanzapine, or risperidone for treatment-resistant schizophrenia. |
2002-03-14 |
2023-08-12 |
Not clear |
| J Mullen, M D Jibson, D Sweitze. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clinical therapeutics. vol 23. issue 11. 2002-03-12. PMID:11768836. |
a comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (quest) study. |
2002-03-12 |
2023-08-12 |
Not clear |
| Lieuwe de Haan, Nico Beuk, Britt Hoogenboom, Peter Dingemans, Don Linsze. Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. The Journal of clinical psychiatry. vol 63. issue 2. 2002-03-08. PMID:11874209. |
obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. |
2002-03-08 |
2023-08-12 |
Not clear |
| Yoram Bara. No weight gain among elderly schizophrenia patients after 1 year of risperidone treatment. The Journal of clinical psychiatry. vol 63. issue 2. 2002-03-08. PMID:11874211. |
no weight gain among elderly schizophrenia patients after 1 year of risperidone treatment. |
2002-03-08 |
2023-08-12 |
Not clear |
| G W MacEwan, T S Ehmann, I Khanbhai, C Wrixo. Donepezil in schizophrenia--is it helpful? An experimental design case study. Acta psychiatrica Scandinavica. vol 104. issue 6. 2002-03-07. PMID:11782241. |
to assess the clinical and cognitive effects of adding donepezil, a reversible acetylcholinesterase inhibitor, to the risperidone treatment of a high functioning stable out-patient with schizophrenia. |
2002-03-07 |
2023-08-12 |
Not clear |
| E Spina, A Avenoso, M G Scordo, M Ancione, A Madia, A Levit. No effect of reboxetine on plasma concentrations of clozapine, risperidone, and their active metabolites. Therapeutic drug monitoring. vol 23. issue 6. 2002-03-07. PMID:11802103. |
the effect of reboxetine on steady-state plasma concentrations of the atypical antipsychotics clozapine and risperidone was studied in 14 patients with schizophrenia or schizoaffective disorder with associated depressive symptoms. |
2002-03-07 |
2023-08-12 |
Not clear |
| Jan Volavka, Pal Czobor, Brian Sheitman, Jean-Pierre Lindenmayer, Leslie Citrome, Joseph P McEvoy, Thomas B Cooper, Miranda Chakos, Jeffrey A Lieberma. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. The American journal of psychiatry. vol 159. issue 2. 2002-03-06. PMID:11823268. |
clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. |
2002-03-06 |
2023-08-12 |
Not clear |
| Jan Volavka, Pal Czobor, Brian Sheitman, Jean-Pierre Lindenmayer, Leslie Citrome, Joseph P McEvoy, Thomas B Cooper, Miranda Chakos, Jeffrey A Lieberma. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. The American journal of psychiatry. vol 159. issue 2. 2002-03-06. PMID:11823268. |
the authors compared the efficacy and safety of three atypical antipsychotics (clozapine, olanzapine, and risperidone) with one another and with haloperidol in the treatment of patients with chronic schizophrenia or schizoaffective disorder. |
2002-03-06 |
2023-08-12 |
Not clear |
| I D Glick, P Lemmens, E Vester-Bloklan. Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents. International clinical psychopharmacology. vol 16. issue 5. 2002-02-27. PMID:11552769. |
treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents. |
2002-02-27 |
2023-08-12 |
Not clear |
| I D Glick, P Lemmens, E Vester-Bloklan. Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents. International clinical psychopharmacology. vol 16. issue 5. 2002-02-27. PMID:11552769. |
combined data on efficacy were available from 12 double-blind short-term (maximum 8 weeks) trials comparing risperidone and other antipsychotics in patients with chronic schizophrenia. |
2002-02-27 |
2023-08-12 |
Not clear |
| I D Glick, P Lemmens, E Vester-Bloklan. Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents. International clinical psychopharmacology. vol 16. issue 5. 2002-02-27. PMID:11552769. |
these findings are consistent with earlier findings that show risperidone is more efficacious than haloperidol for reducing the symptoms of schizophrenia. |
2002-02-27 |
2023-08-12 |
Not clear |
| K S Hong, J G Kim, H J Koh, M S Koo, J H Kim, D Lee, E Ki. Effects of risperidone on information processing and attention in first-episode schizophrenia. Schizophrenia research. vol 53. issue 1-2. 2002-02-22. PMID:11728833. |
effects of risperidone on information processing and attention in first-episode schizophrenia. |
2002-02-22 |
2023-08-12 |
human |
| X Y Zhang, D F Zhou, L Y Cao, P Y Zhang, G Y Wu, Y C She. Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study. International clinical psychopharmacology. vol 16. issue 6. 2002-02-08. PMID:11712620. |
risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study. |
2002-02-08 |
2023-08-12 |
human |
| X Y Zhang, D F Zhou, L Y Cao, P Y Zhang, G Y Wu, Y C She. Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study. International clinical psychopharmacology. vol 16. issue 6. 2002-02-08. PMID:11712620. |
subjects (n = 78) who met dsm-iii criteria for schizophrenia were randomly assigned to receive 6 mg/day of risperidone or 20 mg/day of haloperidol for 12 weeks. |
2002-02-08 |
2023-08-12 |
human |
| X Y Zhang, D F Zhou, L Y Cao, P Y Zhang, G Y Wu, Y C She. Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study. International clinical psychopharmacology. vol 16. issue 6. 2002-02-08. PMID:11712620. |
risperidone appears to be a more effective and better tolerated antipsychotic drug in treatment-refractory chinese schizophrenia than haloperidol. |
2002-02-08 |
2023-08-12 |
human |
| C Miodownik, V Lerne. Risperidone in the treatment of psychotic depression. Clinical neuropharmacology. vol 23. issue 6. 2002-01-30. PMID:11575868. |
risperidone has been primarily marketed for the treatment of schizophrenia. |
2002-01-30 |
2023-08-12 |
Not clear |
| H Y Lane, W H Chang, C C Chiu, M C Huang, S H Lee, J Y Che. A pilot double-blind, dose-comparison study of risperidone in drug-naive, first-episode schizophrenia. The Journal of clinical psychiatry. vol 62. issue 12. 2002-01-25. PMID:11780884. |
a pilot double-blind, dose-comparison study of risperidone in drug-naive, first-episode schizophrenia. |
2002-01-25 |
2023-08-12 |
Not clear |
| N Gupta, D Bas. Does risperidone reduce concomitant substance abuse in cases of schizophrenia? Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 46. issue 9. 2002-01-22. PMID:11761640. |
does risperidone reduce concomitant substance abuse in cases of schizophrenia? |
2002-01-22 |
2023-08-12 |
Not clear |